NeoGenomics(NEO)
Focus: NeoGenomics is a publicly traded diagnostics company specializing in genetic and diagnostic testing for oncology and rare diseases, operating at mid-cap scale with ~500-1000 employees. They leverage genomic sequencing and AI-driven analysis to serve the precision oncology market.
Profile data last refreshed 44m ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
501-1000
Open Jobs
3
Should You Work at NeoGenomics?
AI assessmentNeoGenomics offers diagnostic-sector stability and public-company resources, but persistent operating losses and weak hiring demand make it a selective fit for those prioritizing growth velocity over established market position.
Why Work Here
- Established public company with $592M FY2025 revenue and $367M cash reserves, providing stability in the diagnostics sector.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$592M
Pipeline & Clinical Trials
IO102-IO103 in combination with pembrolizumab
Lung Cancer Non Small CellRecent News · NeoGenomics
Help build intelligence for NeoGenomics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.